Syros Pharmaceuticals (SYRS) News and press releases

Stocks That Hit 52-Week Lows On Monday

20 Mar 23

Options

On Monday, 198 companies hit new 52-week lows.

Syros Pharmaceuticals's Return On Capital Employed Overview

8 Mar 23

Earnings

Tesla To Rally Around 15%? Here Are 10 Other Analyst Forecasts For Friday

3 Mar 23

News, Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas

Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL) from $44 to $41. Credit Suisse analyst Robert Moskow maintained a Neutral rating. Hormel Foods shares fell 1.7% to $41.13 in pre-market trading.

Oppenheimer Maintains Outperform on Syros Pharmaceuticals, Lowers Price Target to $13

3 Mar 23

News, Price Target, Analyst Ratings

Oppenheimer analyst Mark Breidenbach maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Outperform and lowers the price target from $15 to $13.

HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target

3 Mar 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 price target.

Syros Pharmaceuticals Q4 EPS $(0.17) Beats $(1.35) Estimate

2 Mar 23

Earnings, News

Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(1.35) by 87.41 percent. This is a 95.53 percent increase over losses of $(3.80) per share

Earnings Scheduled For March 2, 2023

2 Mar 23

Earnings

Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.

Syros Pharmaceuticals's Earnings Outlook

1 Mar 23

Earnings

12 Health Care Stocks Moving In Thursday's After-Market Session

26 Jan 23

Movers

Analyst Expectations for Syros Pharmaceuticals's Future

5 Jan 23

Analyst Ratings

Piper Sandler Maintains Overweight on Syros Pharmaceuticals, Lowers Price Target to $20

5 Jan 23

News, Price Target, Analyst Ratings

Piper Sandler analyst Edward Tenthoff maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and lowers the price target from $27 to $20.

Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

2 Mar 23

Press Releases

-- Commenced randomized portion of SELECT-AML-1 trial, with initial data expected in 4Q 2023 -- -- Received FDA Fast Track designation for tamibarotene for the treatment of HR-MDS -- -- On-track to complete enrollment

Syros to Participate in Upcoming Investor Conferences in March

28 Feb 23

Press Releases

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer,

Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

23 Feb 23

Press Releases

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9 Feb 23

Press Releases

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

26 Jan 23

Press Releases

-- Currently evaluating tamibarotene in combination with azacitidine pivotal SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed HR-MDS patients with RARA gene overexpression – Syros Pharmaceuticals, Inc.

Syros Announces Clinical Updates and 2023 Strategic Priorities

9 Jan 23

Press Releases

-- Expect to Complete Enrollment in SELECT-MDS-1 Phase 3 Trial in 4Q 2023; Data Expected in 3Q 2024 -- -- On Track to Initiate Randomized Portion of SELECT-AML-1 Phase 2 Trial in 1Q 2023; Initial Data Expected 4Q 2023